Cumulative Dose of Bevacizumab Associates with Albuminuria Rather than Podocyturia In Cancer Patients

Angiogenesis inhibition with bevacizumab, a monoclonal antibody against vascular endothelial growth factor A (VEGF-A), is an anti-cancer treatment associated with hypertension and renal glomerular toxicity referred to as a preeclampsia-like syndrome. In preeclampsia, podocyturia predates proteinuria and clinical features of preeclampsia, and is regarded as a biomarker of ongoing glomerular injury. Using a quantitative polymerase chain reaction (qPCR) of the podocyte-specific molecules nephrin, podocin and VEGF-A in the urine, we examined whether podocyturia is present in bevacizumab-treated cancer patients, and whether it relates to proteinuria and the cumulative dose of bevacizumab.

Source: Journal of the American Society of Hypertension - June 15, 2018 Category: Cardiology Authors: Stephanie Lankhorst, Hans J. Baelde, Jose A.M.C. Verstijnen, Albert J. ten Tije, Marc H.M. Thelen, A.H. Jan Danser, Anton H. van den Meiracker, Mari ëtte H.W. Kappers Tags: Research Article Source Type: research